Rykindo Approved for Schizophrenia, Bipolar Disorder
The approval was based on data from adequate and well-controlled studies with risperidone long-acting injection (intramuscular).
Diagnosis & Disease Information
Aripiprazole 2-Month Under Review for Schizophrenia, Bipolar I Disorder
The NDA is supported by data from a phase 1/2 trial that compared the investigational aripiprazole 2-month, long-acting injectable to aripiprazole 1-month depot.
Xanomeline-Trospium Improves Schizophrenia Symptoms in Phase 3 Trial
The phase 3 EMERGENT-2 trial included 252 patients with schizophrenia who were experiencing symptoms of psychosis.
Speech-Gesture Training Improves Quality of Life for Patients With Schizophrenia
To assess the impact of multimodal speech-gesture training on patients’ communication abilities, investigators conducted a randomized waiting list-controlled pilot trial at a university in Marburg, Germany.
Cognitive Enhancement Therapy May Improve Some Schizophrenia Symptoms
The researchers conducted secondary analysis of a multi-site CET trial using 86 individuals recently diagnosed with a schizophrenia spectrum disorder.
Igalmi Sublingual Film Approved for Agitation With Schizophrenia, Bipolar Disorder
The approval was based on data from the phase 3 SERENITY I and II studies that evaluated Igalmi for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II, respectively.
New Tool May Help Reduce CVD Risk in Patients With Mental Illnesses
A clinical decisions support system provides personalized treatment recommendations on lowering cardiovascular risk factors in patients with schizophrenia, schizoaffective disorder, and bipolar disorder.
Treatment-Resistant Schizophrenia May Have Genetic Cause
The results of a genome-wide association study may help researchers develop more tailored treatments to help patients who don’t respond to conventional antipsychotic medications.
Psychosis Risk Influenced by Early-Life Infection, Inflammation, and Metabolic Alterations
Three-quarters of all psychiatric disorders occur by early adulthood (mid-20s). This fact suggests that bio-psychosocial factors occurring from the fetal period through early adulthood could play a crucial role in risk. This nonsystematic review sought to synthesize key epidemiological evidence of relevant risk factors.
People With Schizophrenia at High Risk of Dying From COVID-19
With people who have major psychiatric disorders being more likely to have comorbidities which could lead to worse results concerning COVID-19, researchers using a US database assessed the odds of testing positive for COVID-19, as well as mortality from COVID-19.
- Loading...
Loading...
Next post in Medicine
Loading... 
Loading...